Following allergy to pegaspargase, Erwinia asparaginase 25,000-IU/m 2 x 6 doses IM M/W/F can be substituted for a single dose of pegaspargase. 
Introduction
Following the first reported use of asparaginase in an 8 year old boy with relapsed acute lymphoblastic leukemia (ALL) in 1966 1 , single agent studies in the early 1970s of asparaginase for the treatment of children diagnosed with ALL demonstrated response rates of 20-68% [2] [3] [4] [5] [6] [7] .
Since this time, asparaginase has become an essential component of multi-agent chemotherapy for childhood ALL 3, 4, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] .
In the United States prior to November 2011, two asparaginase preparations received approval for use by the Food and Drug Administration (FDA), native E. coli asparaginase and pegaspargase. Pegaspargase has been the more commonly used product because it requires less frequent administration than E. coli asparaginase as a consequence of its longer biological halflife, and because of its lower immunogenicity [17] [18] [19] [20] [21] . A third preparation, Erwinia asparaginase, derived from the bacterium Erwinia chrysanthemi, was not commercially available in the United
States during the conduct of this study but was available on a compassionate use basis.
Pegaspargase has been the sole asparaginase preparation used in Children's Oncology ≥ 0.10-IU/mL, which has been associated with complete asparagine depletion 22, 23 .
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Patients and Methods

Patients
Eligible patients on COG AALL07P2 were >1 to <30 years of age, currently enrolled on a frontline COG ALL treatment study, had documented For personal use only. on October 22, 2017. by guest www.bloodjournal.org From
Determination of Serum Asparaginase Activity
Twelve blood samples (2-mL) were scheduled for collection from each patient during course 1: prior to each Erwinia asparaginase dose; on days 15 and 22 post-administration; and at 2-and 24-hours following doses 1 and 4 for patients beginning treatment on Monday or Wednesday or doses 2 and 5 for patients beginning treatment on Friday. Additional samples were collected before administering doses 1 and 6 and on day 15 during all subsequent courses of therapy.
Blood was allowed to clot for 1-2-hours over ice before centrifuging (1,300-g, 10-min, 4ºC).
Serum was removed and stored at -70°C until packaged for shipment to a central laboratory for analysis.
Asparaginase activity was determined by a coupled enzymatic assay as previously reported with minor modifications 17, 25 . Briefly, aspartic acid formed from the asparaginase catalyzed deamination of added asparagine reacts with α -ketoglutaric acid in the presence of glutamic-oxaloacetic transaminase, yielding oxaloacetic acid, which oxidizes reduced β -nicotinamide adenine dinucleotide in the presence of malic dehydrogenase, resulting in a decrease in absorbance at 340-nm. The rate of reaction at 37°C is a linear function of enzyme activity. E. coli asparaginase purchased from Sigma (St. Louis, MO) was used as the analytical reference standard to prepare a series of seven calibration standards in normal human serum with activities of 0.025-0.25-IU/mL. Samples with activities exceeding the upper range of the calibration curve were reanalyzed after diluting with normal human serum. Back-calculated asparaginase activities from a total of 81 calibration curves were used to assess the between day accuracy and precision of the assay during its application to samples from this study. Accuracy was 97.0% of the nominal activity and the precision was 6.0% at the 0.025 IU/mL lower limit of quantitation. Quality control samples with asparaginase in serum at activities of 0.035, 0.120, 7 and 0.220-IU/mL were assayed with a between-day accuracy of 99.1-102.1% and a precision of 4.7-5.8%.
Statistical Analysis of Serum Asparaginase Activity Data
This study was powered to test the hypothesis that the 48 hour NSAA would be ≥ 0.1-IU/mL in at least 70% of patients versus meeting this target activity in 50% of patients. A Simon "minimax" two-stage design was used with a total sample size of 50, to distinguish between a true null response probability of 70% versus a true alternative response probability of 50% with a significance level of 5%, and 90% power. A total of 31 patients were to be accrued in the first 
Pharmacokinetic Modeling
Serum asparaginase activity-time data for the 6 doses of IM Erwinia asparaginase given during the first course of therapy were fit to a one compartment open model with first-order absorption by unweighted nonlinear regression using WinNonlin Professional 5.0 (Pharsight Corp., Cary, NC). Data for each patient was initially fit to the equation,
with the repeated dosing option, where A s (t) is the serum asparaginase activity at time t relative to the first dose, k a is the apparent rate constant for absorption of enzyme from the extravascular administration site into serum, k e is the apparent rate constant for the loss of serum enzyme activity, V/F is the extravascular apparent volume of distribution, and D is the dose. In cases
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which is also included in the WinNonlin library of pharmacokinetic models. Pharmacokinetic variables (i.e. half-lives, apparent extravascular clearance, maximum serum asparaginase activity and time) were calculated by the program using final values of the iterated parameters (i.e. V/F, k a , k e ). The two-tailed t-test was used to compare mean pharmacokinetic variables between groups of patients after logarithmic transformation of the data. A p-value <0.05 was the criterion for statistical significance.
Results
Patient Characteristics
Fifty-nine patients were enrolled on AALL07P2 ( Figure 1 ). Patients were also enrolled on one of six upfront studies, AALL0232, AALL0331, AALL0434, AALL07P4, AALL0622, and AALL08P1, where planned doses of pegaspargase varied by study arm and ranged from 1-13. Fifty-eight enrolled patients received at least one dose of Erwinia asparaginase and are included in the safety analysis ( Table 1 ). The mean age at study entry was 9.7 years (range 2-18) and majority were male (34 [58.6%]). Fifty-one (87.9%) patients had B-precursor ALL and 7 (12.1%) had T-ALL. All patients were within 9 months of diagnosis (50% 0-3 months, 44.8% 4-6 months, 5.2% 7-9 months). Patients received a median of 3 (range 1-5) doses of pegaspargase prior to enrollment on AALL07P2 and received a median of 3 (range 1-9) courses of Erwinia asparaginase. Fifty-five patients were eligible and evaluable for AALL07P2, and 44/55 (80%) patients were able to complete all remaining courses of planned asparaginase therapy.
Toxicity
Grade 2-3 allergic reaction, grade 1-3 hyperglycemia, and grade 1 pancreatitis related to Erwinia asparaginase were reported in 6, 6 and 1 patients, respectively (Table 2 ). There were no reports of hemorrhage, thrombosis, hyperlipidemia, ketoacidosis, or death.
Nadir Serum Asparaginase Activity
The primary endpoint was based upon a single 48-hour NSAA determination in 41 patients during course 1. Samples from 14 patients were excluded from statistical analysis because they were either not obtained, collected at a time differing from 48-hours by more than 5%, dosing or sample collection times were not recorded, or due to dosing inconsistencies. The 
Pharmacokinetics of Serum Asparaginase Activity
Serum asparaginase activity-time data obtained during treatment with the 6 doses of Erwinia asparaginase given in the first course of therapy were amenable to pharmacokinetic analysis for a total of 54 patients. A sparse sampling schedule was employed in which asparaginase activity was monitored at 10 time points over a time interval of 14-days to enable patients to be treated with minimal inconvenience on an outpatient basis. Although it is not possible to estimate any pharmacokinetic parameters by non-compartmental methods of analysis, simultaneously fitting the entire data set by nonlinear regression to a one compartment open model with first-order absorption, using the repeated dosing option for the model, yielded an acceptable fit of the experimental data for all patients.
The existence of two distinct populations of patients was discerned for which the estimated values of k a and k e were either well differentiated (group A) or kinetically indistinguishable (group B). Specifically, the average k a /k e ratio was 6.6 (range, Mean values of the parameters describing the best-fit equations and derived variables are presented separately in Table 4 for both groups of patients. The mean CL/F was not significantly different (P=0.33) for the two groups whereas V/F was approximately 50% greater for group A than group B (P=0.0045). Consequently, there was a difference of similar magnitude in the mean apparent biological half-life of serum asparaginase activity between the two groups, which was 22.1±7.7-hours for group A as compared to 12.6±2.1-hours for group B (P<0.001). The maximum predicted asparaginase activity for the first dose of Erwinia asparaginase was not significantly different (P=0.41) for the two pharmacokinetic groups, although the time that it occurred was earlier (P<0.001) for group A patients (13.0±5.3-hours) than group B (18.2±3.1-hours).
More of the patients started therapy on a Wednesday (44%) than either a Monday (26%) or Friday (28%). The mean asparaginase activity-time course for the 24 patients with a
Wednesday starting day is shown in Fig. 2B . The predicted maximum asparaginase activity Asparaginase has become a critical component of multi-agent chemotherapy for the treatment of ALL 3,4,7,9-13 . Current chemotherapy regimens for pediatric ALL typically include a post-induction intensification phase during which asparaginase is routinely administered 25,39-42 .
All COG trials for newly diagnosed patients with ALL, with the exception of infant ALL, administer pegaspargase starting during induction therapy and as the sole asparaginase product.
However, allergic reactions develop in many patients treated with pegaspargase. In addition, immunologic responses to all asparaginase preparations are associated with formation of . It has been suggested that treatment with lower doses of Erwinia asparaginase given daily or on alternating days could be more effective than higher but less frequent doses in producing complete and sustained asparagine depletion 37 . Specifically, the MWF schedule was recommended when substituting Erwinia asparaginase for weekly E. coli asparaginase 47 . The dose of Erwinia asparaginase is also a critical consideration, as only 33% of the patients receiving a 10,000-IU/m 2 dose IM once every 3 days had mean trough levels ≥ 0.10 IU/mL 48 .
The results of COG AALL07P2 showed that of the 55 eligible/evaluable patients NSAA In another study, the plasma pharmacokinetics of asparaginase activity was characterized in 13 pediatric ALL patients receiving daily doses of 30,000-IU/m 2 Erwinia asparaginase given either as a 3-hour IV infusion or IM injection 18 . Asparaginase activity decayed with a mean half-life of 6.4±1.9-hours when the enzyme was given by the IV route. The mean total body clearance of Erwinia asparaginase was 0.16±0.06-liters/hour/m 2 and it had a mean apparent pharmacokinetics, also commonly known as the "flip-flop phenomenon", when given by the IM route. Under these circumstances, the smaller rate constant derived from the terminal region of decreasing drug levels actually corresponds to k a whereas the larger rate constant derived from the early region of increasing drug levels corresponds to k e 50 . This association is strictly true only if the ratio between the larger and small rate constant is sufficiently large (i.e., >3),
otherwise estimated values of the rate constants do not approximate either the true k a or k e .
Results obtained from our study, which involves considerably more patients than previously evaluated, confirms the absorption rate-limiting pharmacokinetics of IM Erwinia asparaginase. Two subpopulations of patients, each of which comprised approximately 50% of the total cohort, were identified by the relative magnitude of k a and k e . Patients designated as group A had kinetically distinguishable apparent rate constants and those designated as group B did not. The mean k a for group A patients (0.15±0.09-hours -1 ) is in very good agreement with the mean k e previously reported for the loss of asparaginase activity following IV administration of Erwinia asparaginase in 13 patients (0.12±0.04-hours -1 ) 18 . In this earlier study, the apparent k e for IM Erwinia asparaginase could only be estimated for 7 of the 16 patients evaluated (44%).
It is perhaps more than coincidental that this is similar to the proportion of patients in the present study whose enzyme activity-time data were described by equation A of the pharmacokinetic model (i.e. 48%). In any event, the mean k e for group A patients (0.031±0.013-hours -1 ) was very similar to the apparent k e reported for the 7 patients receiving IM Erwinia asparaginase in the prior study (0.034±0.005-hours -1 ).
The mean apparent half-life of serum asparaginase activity is almost two-fold shorter for patients in group B as compared to group A. Enzyme absorption from the IM injection site remains rate-limiting for group B patients because the mean apparent half-life in these patients is still 2-times larger than the mean half-life reported for IV administration of the enzyme. It follows that patient specific factors, which remain to be identified, are probably responsible for influencing the rate of absorption of the enzyme from the IM injection site into systemic circulation, resulting in the observed differences in the pharmacokinetic behavior of asparaginase activity between the two subgroups. The very low bioavailability of IM Erwinia asparaginase, which was reported to be only 27.1% on average and highly variable between patients, as indicated by a 57.7% coefficient of variation, lends additional plausibility to this hypothesis 18 .
Relatively minor changes in the rate or extent of absorption of the enzyme would have a marked effect on the time course of serum asparaginase activity under these circumstances. Most importantly, the effect does not appear to be clinically relevant for the Erwinia asparaginase dosing regimen evaluated in this study because serum asparaginase activity remained above the 0.10-IU/mL therapeutic threshold for up to 72-hours after dosing in 84.5% of acceptable samples.
The DFCI 95-01 and EORTC-CLG 58881 40, 46 , suggested that toxicities associated with Erwinia asparaginase therapy were less than those associated with E. coli asparaginase. These studies however failed to dose adjust Erwinia asparaginase based on its shorter half-life, raising concern that sub-optimal dosing may have resulted in fewer toxicities. The AALL07P2 dosing schedule of 25,000-IU/m 2 on a MWF schedule resulted in few clinically significant toxicities.
Because of the sample size of this study, firm conclusions cannot be made on the incidence of these targeted toxicities.
In conclusion, Erwinia asparaginase administered IM using the MWF AALL07P2 regimen was well tolerated and achieved a therapeutic NSAA at both 48-and 
